IANS Advanced HRA Course

Draft Agenda

Friday November 14th

12:00  Registration

1:00   Opening Remarks – J. Palefsky, M.D.

1:15   HPV Update: epidemiology of HPV in the anus and other sites – what’s new?- J. Palefsky, M.D.

2:05   Pathology for the non-pathologist: new developments in pathology, including biologic markers, and the LAST terminology – T. Darragh, M.D.

2:55   Q & A

3:15   Coffee Break

3:30   Panel Discussion: Intra-anal challenging cases:

    1. The obscured exam: different reasons exams can be technically difficult, tips for visualizing under trying circumstance
    2. The discordant exam: cytology, histology or clinical discordant results
    3. There’s more than mosaic patterns and punctation: recognizing other lesion characteristics and the distal canal

4:30   Workshop I: Case-based discussions

Emphasis on difficult HRA, lesion recognition, distal canal disease, management strategies to include:

Cases of discordance and how to manage

Hemorrhoids and prolapse

Getting to the folds

Distal canal lesions

6:10   Adjourn

6:30   Optional: Meet & Greet the faculty and fellow attendees

Saturday November 15th

7:00   Breakfast (provided)

7:30   Faculty available for Q & A

7:45   Dermatology of the Perianus: Rachel Kornik, M.D.

8:30   Q&A

8:45   Advanced HRA of the perianus: recognizing HSIL and Cancer – N. Jay, RN NP

9:30   Q & A

9:45   Panel Discussion: Perianal disease

  1. Treating perianal disease: different strategies
  2. How to do a good perianal work-up
  3.  Under-treated, recurrent disease, or chronic recurrent disease

10:45  Coffee Break

11:00  Workshop cases: Dermatology and perianal disease

Is it HSIL, is it something else, where would you biopsy?

This looks bad – how would you treat it

Cases of difficult management

Anal/vulvar disease

Anal/scrotal disease

12:40   Lunch Break (provided)

 1:30   Lecture: Basic science – advanced immunology and virology, what’s new – Joel Palefsky, M.D.

 2:30   Proctology: recognition of non-HPV anal disease and management – Steve Goldstone, M.D.

 3:30   Q & A

 3:45   Coffee Break

 4:00   Panel: We have identified HSIL, we can do HRA, but now what?

 Controversies in Screening, Treatment and Management:

Screening: not ready for primetime
Optimal screening and follow up: the role of cytology, DARE, HRA, HPV
Identification of populations for screening

5:00   Workshops: screening and follow up algorithms: potential management strategies following diagnosis and treatment of HSIL

6:00   Q&A

6:30   Adjourn


Sunday November 16th

7:00   Breakfast (provided)

7:30   Faculty available for Q & A

7:45   The art of anal whispering - C. Law, M.D.

8:30   Q&A

8:45   Anal Cancer: new strategies for treatment and management – Michael Berry, M.D.

9:30   Q&A

9:45   Up Close and Personal: anal cancer survivor’s perspective

10:30  Q&A

10:45  Coffee break

11:00  Panel: Management of the Patient with Anal Cancer:

Metastatic and recurrent: what are their options

Taking care of treatment related symptoms: incontinence, bleeding, impotence, inability to have anal sex

Post-cancer treatment management

12:00   Workshops: cancer-related case discussions


Post treatment management and HRA findings post-radiation

Cancer found subsequent to ablation

Recurrent cancer work-up

Frank presentation with equivocal biopsy

1:00   Summary and Wrap-Up

1:30   Adjourn

International Anal Neoplasia Society

PO Box 2023
Montgomery Village, Maryland 20886
Fax 301-330-5028
Powered by Wild Apricot Membership Software